RTN4R and neoplasm: The tumor vasculature-homing properties of the CNGRCG-TNF fusion protein (called NGR-TNF) allows the targeted delivery of extremely low, yet pharmacologically active doses of TNF to tumor blood vessels, thereby avoiding systemic toxicity (Figure 2B).